Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 8
October 30, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 2023
October 20, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
– 17 abstracts accepted, including new and encore data emphasizing clinical benefit and patient preference for a once-at-bedtime narcolepsy treatment option – – Company to host symposium on October...
Avadel Pharmaceuticals to Present at the Jefferies Biotech CNS/Neuro Summit
October 05, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
August 31, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 09, 2023 07:00 ET
|
Avadel Pharmaceuticals plc
-- Successfully commenced U.S. commercial launch of LUMRYZ™-- -- Received final FDA approval for LUMRYZ with orphan drug exclusivity granted through May 1, 2030 -- -- Significant early...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9
August 02, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
July 20, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, July 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
July 06, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, July 06, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Pharmaceuticals to Host Commercial Day on June 29 for LUMRYZ™ (sodium oxybate) extended release for oral solution, CIII
June 22, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, June 22, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...